Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UIS9
UPID:
MBD1_HUMAN
Alternative names:
CXXC-type zinc finger protein 3; Methyl-CpG-binding protein MBD1; Protein containing methyl-CpG-binding domain 1
Alternative UPACC:
Q9UIS9; A4UTZ0; B4DXJ5; E9PEC5; K7ELI2; K7EQZ4; K7ESN0; O15248; O95241; Q7Z7B5; Q8N4W4; Q9UNZ6; Q9UNZ7; Q9UNZ8; Q9UNZ9
Background:
Methyl-CpG-binding domain protein 1, also known as MBD1, plays a crucial role in transcriptional repression by binding to methylated CpG islands in gene promoters. This protein, with alternative names such as CXXC-type zinc finger protein 3 and Protein containing methyl-CpG-binding domain 1, is pivotal in gene silencing through its interaction with ATF7IP and SETDB1, facilitating DNA methylation and histone modification.
Therapeutic significance:
Understanding the role of Methyl-CpG-binding domain protein 1 could open doors to potential therapeutic strategies. Its involvement in transcriptional repression and gene silencing highlights its significance in gene expression regulation, offering a promising avenue for exploring novel treatments.